Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?

Seyed Parsa Eftekhar, View ORCID ProfileSohrab Kazemi, View ORCID ProfileMohammad Barary, View ORCID ProfileMostafa Javanian, View ORCID ProfileSoheil Ebrahimpour, Naghmeh Ziaei
doi: https://doi.org/10.1101/2021.01.16.21249941
Seyed Parsa Eftekhar
1Student Research Committee, Health Research Center, Babol University of Medical Sciences, Babol, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sohrab Kazemi
2Cellular and Molecular Biology Research Center, Health Research Center, Babol University of Medical Sciences, Babol, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Sohrab Kazemi
Mohammad Barary
1Student Research Committee, Health Research Center, Babol University of Medical Sciences, Babol, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammad Barary
Mostafa Javanian
3Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mostafa Javanian
Soheil Ebrahimpour
3Infectious Diseases and Tropical Medicine Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R. Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Soheil Ebrahimpour
Naghmeh Ziaei
4Department of Cardiology, Babol University of Medical Sciences, Babol, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ziaiexn@yahoo.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Hydroxychloroquine with or without azithromycin was one of the common therapies at the beginning of the COVID-19 pandemic. They can prolong QT interval, cause Torsade de pointes, and lead to sudden cardiac death. We aimed to assess QT interval prolongation and its risk factors in patients who received hydroxychloroquine with or without azithromycin.

Methods This was a retrospective cohort study. 172 patients with COVID-19 included, hospitalized at hospitals of Babol University of Medical Sciences between March 5, 2020, and April 3, 2020. Patients were divided into two groups: hydroxychloroquine alone and hydroxychloroquine with azithromycin. Electrocardiograms were used for outcome assessment.

Results 83.1% of patients received hydroxychloroquine plus azithromycin vs 16.9% of patients who received only hydroxychloroquine. The mean age of patients was 59.2 ± 15.4. The mean of post-treatment QTc interval in the monotherapy group was shorter than the mean of post-treatment QTc interval in the combination therapy group but it had no significant statistical difference (462.5 ± 43.1 milliseconds vs 464.3 ± 59.1 milliseconds; P = 0.488). Generally, 22.1% of patients had a prolonged QTc interval after treatment. Male gender, or baseline QTc ≥ 450 milliseconds, or high-risk Tisdale score increased the likelihood of prolonged QTc interval. Due to QTc prolongation, 14 patients did not continue therapy after 4 days.

Conclusion Hospitalized patients treated with hydroxychloroquine with or without azithromycin, had no significant difference in prolongation of QT interval and outcome. But the number of patients with prolonged QT intervals in this study emphasizes careful cardiac monitoring during therapy; especially in high-risk patients.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

The authors declare no competing financial interest.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study has been approved by the ethics committee of Babol University of Medical Sciences (Babol, Iran).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?
Seyed Parsa Eftekhar, Sohrab Kazemi, Mohammad Barary, Mostafa Javanian, Soheil Ebrahimpour, Naghmeh Ziaei
medRxiv 2021.01.16.21249941; doi: https://doi.org/10.1101/2021.01.16.21249941
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Hydroxychloroquine and azithromycin: As a double edge sword for COVID-19?
Seyed Parsa Eftekhar, Sohrab Kazemi, Mohammad Barary, Mostafa Javanian, Soheil Ebrahimpour, Naghmeh Ziaei
medRxiv 2021.01.16.21249941; doi: https://doi.org/10.1101/2021.01.16.21249941

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Cardiovascular Medicine
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (172)
  • Anesthesia (51)
  • Cardiovascular Medicine (456)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (160)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (192)
  • Epidemiology (5315)
  • Forensic Medicine (3)
  • Gastroenterology (199)
  • Genetic and Genomic Medicine (764)
  • Geriatric Medicine (81)
  • Health Economics (216)
  • Health Informatics (704)
  • Health Policy (364)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (166)
  • Infectious Diseases (except HIV/AIDS) (5967)
  • Intensive Care and Critical Care Medicine (368)
  • Medical Education (106)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (781)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (146)
  • Occupational and Environmental Health (237)
  • Oncology (483)
  • Ophthalmology (155)
  • Orthopedics (40)
  • Otolaryngology (98)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (224)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (868)
  • Public and Global Health (2051)
  • Radiology and Imaging (356)
  • Rehabilitation Medicine and Physical Therapy (160)
  • Respiratory Medicine (288)
  • Rheumatology (95)
  • Sexual and Reproductive Health (75)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (30)
  • Urology (40)